Korea Innovative Medicines Consortium
Overview
Korea Innovative Medicines Consortium is a non-profit foundation established by South Korean pharmaceutical and biotechnology companies to serve as a collaboration platform for co-investment and co-development in the bio-pharma industry.
Investments
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Korea Innovative Medicines Consortium based?
Korea Innovative Medicines Consortium is headquartered in Seoul, South Korea.
When was Korea Innovative Medicines Consortium founded?
Korea Innovative Medicines Consortium was founded in 2020.
How many portfolio companies does Korea Innovative Medicines Consortium have?
Korea Innovative Medicines Consortium has 3 portfolio companies in Caplight's dataset.
What are some companies in Korea Innovative Medicines Consortium's portfolio?
Portfolio companies visible on Caplight include Neumous, Gedit, BreezeBio.
What was Korea Innovative Medicines Consortium's most recent investment shown here?
Korea Innovative Medicines Consortium's most recent investment in this portfolio sample was in Neumous in 2025.
What sectors does Korea Innovative Medicines Consortium focus on?
Korea Innovative Medicines Consortium focuses on Healthcare & Life Sciences, Enterprise Software, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Korea Innovative Medicines Consortium focus on?
Korea Innovative Medicines Consortium typically invests at the Early stage.
What is Korea Innovative Medicines Consortium's AUM?
Korea Innovative Medicines Consortium's assets under management are estimated between $11.9M and $11.9M.